Tempest Therapeutics, Inc. TPST
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
Tempest Therapeutics, Inc. (TPST) is a healthcare company listed in the US with a market value of about $8M.
Its overall Stock Analiz score is 0.0 out of 5 (weak). The strongest part is value (0/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -79%.
About Tempest Therapeutics
Tempest Therapeutics is listed in the US and classified in biotechnology: pharmaceutical preparations. It was profitable in 0 of the last 10 years in our data. Its share count rose by 367% over three years (dilution for shareholders).
Score: 0.0 / 5
Checks passed
- —
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — | $295000 | $653000 |
| Net income | -$26M | -$42M | -$29M | -$36M | -$28M | -$19M | -$45M | -$27M | -$85M | -$82M |
| Free cash flow | -$27M | -$33M | -$28M | -$32M | -$26M | -$19M | -$42M | -$24M | -$20M | -$64M |
| EPS (diluted) | $-1.27 | $-3.90 | $-4.97 | $-8.03 | $-19.42 | $-106.68 | $-8.45 | $-45.71 | $-836.71 | $-903.48 |
| Net margin | — | — | — | — | — | — | — | — | -28670.5% | -12597.2% |
| ROIC | -141.8% | -96.1% | -48.6% | -68.0% | -39.0% | — | — | -29.7% | — | -59.1% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 1 analysts is $7.00, 1733% above the current price; targets range from $7.00 to $7.00; the consensus rating is “none”; expected EPS is $-2.85 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Tempest Therapeutics pay a dividend?
Not currently.
Is Tempest Therapeutics a good stock to buy?
We do not give buy or sell advice. Tempest Therapeutics scores 0.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.